Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 7—July 2012


Dobrava Hantavirus Infection Complicated by Panhypopituitarism, Istanbul, Turkey, 2010

Nevin Sarıgüzel1Comments to Author , Jörg Hofmann1, Alper Tunga Canpolat, Ali Türk, Jakob Ettinger, Deniz Atmaca, Işın Akyar, Serap Yücel, Ender Arıkan, Yavuz Uyar, Dilek Y. Çağlayık, Ayşe Sesin Kocagöz, Ayşin Kaya, and Detlev H. Kruger
Author affiliations: Acıbadem Hospital, Istanbul, Turkey (N. Sarıgüzel, A.T. Canpolat, D. Atmaca, Serap Yücel, Ender Arıkan); Charité University Medicine, Berlin, Germany (J. Hofmann, J. Ettinger, D.H. Kruger); Labor Berlin Charité-Vivantes GmbH, Berlin (J. Hofmann, J. Ettinger, D. H. Kruger); Acıbadem University, Istanbul (A.Türk, I. Akyar, A. S. Kocagöz); Refik Saydam National Public Health Agency, Ankara, Turkey (Y. Uyar, D. Y. Çağlayık); and University of Geneva, Geneva, Switzerland (A. Kaya)

Main Article

Table 2

Characterization of DOBV hantavirus in a patient’s serum by focus reduction neutralization tests, Istanbul, Turkey, 2010*

Day of hospitalization Focus reduction neutralization test endpoint titer
Puumala hantavirus Hantaan virus DOBV-Aa (strain SK) DOBV-Af (strain Slo)
5 <1:40 <1:40 1:640 1:1,280
26 <1:40 <1:40 1:160 1:320

*DOBV, Dobrava-Belgrade virus; Aa, Apodemus agrarius; Af, Apodemus flavicollis; SK, strain Slovakia; Slo, strain Slovenia.

Main Article

1These authors contributed equally to this article.

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO